Today, a new approach is giving patients and their physicians reason to hope. Moffitt Cancer Center has expanded its ...

In vivo platform enables efficient, site-specific CAR gene insertion under control of an endogenous T cell promoter, producing functional CART ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

The first three patients to undergo the procedure did so without complication and were discharged as planned, Rabin Medical Center announced.

Chimeric antigen receptor (CAR) T-cell therapy has been an exciting area of development for autoimmune disease treatment. Previous reports had not mentioned any particular constellation of adverse ...

“Your cancer has spread” is terrifying news to hear. But it’s unfortunately common for people with colorectal cancer. The cancer is the third most common tumor globally and accounted for 930,000 ...

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

A new international multicenter study published in the Journal of Cellular and Molecular Medicine provides important real-world evidence on the use of CD19-targeted chimeric antigen receptor (CAR) ...